Alnylam Pharmaceuticals has announced a $250 million investment to expand its manufacturing facility in Massachusetts. The ...

Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...

Nimbus Therapeutics announced it has entered into a multi-year research collaboration and $1.3 exclusive license agreement ...

Ketamine's rapid antidepressant effects have led to a significant increase in off-label psychiatric use, despite the lack of ...

Humans also create value through ethical restraint, the ability to recognize when not to cut corners, when to delay, and when to prioritize patient safety or scientific rigor over speed. That human ...

The collaboration with Sanofi focuses on developing bispecific antibodies for autoimmune diseases, leveraging predictive ...

In today’s Pharmaceutical Executive Daily, the Wegovy Pill becomes the first available oral GLP-1 for weight management, ...

Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America ...

FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...

In 2024, AbbVie’s presentation at the conference focused on its recent acquisitions of ImmunoGen and Cerevel. AbbVie paid ...

Hoth Therapeutics filed two provisional patent applications with the U.S. Patent and Trademark Office, expanding the ...

As has been the case for the past several years, industry experts will be focused on Merck at the 44 th Annual JP Morgan ...